Your Health, We Care
Release date: 2024-08-16 17:47:37 Recommended: 158
In May 2020, Selpercatinib was approved by the FDA for the treatment of various cancers caused by RET gene mutations. The drug stops the spread of the lesion by interfering with the signaling pathways of cancer cells. Clinical studies have shown that it has shown good efficacy in multiple cancer types.
Treatment-naïve patients with RET fusion-positive non-small cell lung cancer
63%, similar to the combination chemotherapy group, indicating significant effectiveness in treatment-naïve patients.
Of the 5 patients with CNS metastases at baseline, 4 patients experienced a treatment response to intracranial lesions, further confirming the effectiveness of this treatment for treatment-naïve patients with brain metastases.
Among treatment-naïve patients who responded to intracranial lesions, 38% of patients achieved or exceeded intracranial remission for 12 months, comparable to that of the prior treatment group, demonstrating the durable effect of treatment on brain metastases in treatment-naïve patients.
When using Selpercatinib, be aware of the following drug interactions, which are important for the patient's treatment process.
Concomitant use with strong or moderate CYP3A inducers reduces plasma concentrations of Selpercatinib and may weaken the antitumor effect of the drug. Avoid this combination of medications. If unavoidable, the regimen of Selpercatinib should be adjusted to maintain the response to treatment.
Selpercatinib is a moderate CYP2C8 inhibitor and a weak CYP3A inhibitor. When used with these substrate drugs, it may increase the plasma concentration of the substrate and increase the risk of adverse effects. If used with these drugs, it is recommended to follow the label of the substrate drug for dose adjustment and closely monitor for associated adverse effects.
The main indications for Selpercatinib include the following cancer types, please refer to the label for details.
Selpercatinib can be used for specific cholangiocarcinomas, including those with inoperable advanced or metastatic cases. Patients should have FGFR2 fusions or other FDA-approved genetic rearrangement features.
For adult patients, Selpercatinib can be used for relapsed or refractory myeloid/lymphoid tumors, particularly those with FGFR1 rearrangements.
[Warm tips] Before starting any new medication or supplement, inform your doctor or pharmacist about the medication you are currently taking to avoid possible drug interactions.
